

FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS' CLINICAL CONTRIBUTIONS IN HOSPITAL

Paul Wright*, Rhona Sloss*, Reena Mehta**, Raliat Onatade*

*Pharmacy Department, Barts Health NHS Trust **Pharmacy Department, King's College Hospital

Background

There are few validated instruments for rating clinical significance of pharmacy contributions to care with no accepted gold standard.¹ We sought to finalise validation of the IMPACCTS (InstruMent for PhArarmacy Clinical Contributions To care Significance) tool which consists of:

- 5 ordered levels
- Each level underpinned by descriptive statements (45 in total)
- A 6th level (level 0) denoting a contribution deemed inappropriate or potentially harmful

A robust process to ensure simplicity and clarity of the instrument has previously been reported.^{2,3}

Aims and Objectives

To finalise validation of IMPACCTS by:

- Demonstrating comprehensiveness of the instrument. Aiming for 100% of scenarios to be assigned a statement using IMPACCTS
- Quantifying interrater reliability

IMPACCTS – InstruMent for rating PhArarmacy Clinical Contributions To care Significance

- IMPACCTS is a pharmacy clinical contributions severity rating scale for potential patient outcome
- The tool has six clinical significance **levels** (0 to 5)
- Under each significance level there are a number of **statements** which describe different types of clinical pharmacy contributions


Level 0 – Leads or could lead, to an undesirable outcome/pharmacist's actions were inappropriate.
Level 1 – Good practice leading to no harm or clinical benefit to the patient. • Substituting a drug to comply with formulary. <i>Note: If there is a clinical reason for change, it should be graded higher</i>
Etc...
Level 2 – Minor benefit to patient OR made treatment easier OR prevented minimal harm OR an error/incident which could have required non invasive monitoring. • Action taken to avoid dosing error where the risk of harm OR likelihood of benefit is not significant.
Etc...
Level 3 – Level 3 contributions are those which will provide significant benefit to patient OR prevented an incident of significant harm OR without which would have required additional treatment or invasive intervention. • Any action including medicines rationalisation to prevent noticeable discomfort or provide significant benefit.
Etc...
Level 4 – Prevented an incident that could have potentially led to reversible organ failure, major reversible harm or increased level of care (i.e. *readmission into hospital, or from L1 to L2, or L2 to L3) *Re-admission – If you consider readmission to be the most likely outcome, the minimum level to assign is level 4, however you may wish to assign a higher level, depending on your judgement of the severity of the impact on the patient. • Action taken to resolve the problem of a dose of a drug which would result in serum drug levels in the toxic range, where patient is at risk of reversible organ damage.
Etc...
Level 5 – Prevented an incident that could have resulted in a life or death situation, permanent organ damage or severe harm, OR an error which could have potentially caused major permanent harm. • Action taken to change the dose of a potentially lifesaving drug (i.e. any drug which could prevent or treat a life-threatening condition) which is too low for the patient.
Etc...

Method

Comprehensiveness



Interrater Reliability



Results

Comprehensiveness


- For all scenarios, at least one person found a statement.
- A statement and/or level could be assigned for 99.8% of scenarios by two pharmacists.

Interrater Reliability

- Intraclass correlation was 0.71 (95% CI = 0.55, 0.86), equalling moderate to good pharmacist agreement.^{4,5}

Conclusion

- Excellent comprehensiveness and moderate to good interrater reliability of IMPACCTS has been demonstrated.
- The instrument is ready for widespread adoption in both research and practice to assess the clinical severity of pharmacy contributions.
- IMPACCTS is only validated for use in UK hospitals at this time.
- Repeat studies would be needed to confirm appropriateness for use in other pharmacy settings.



Breakdown of comprehensiveness results (n = 450)

References

- ¹Vo TH et al. *Drug Safety* (2016);39(2): 131-46.
- ²Ali F et al. *United Kingdom Clinical Pharmacy Association Symposium Proceedings*; 2021.
- ³Mehta R and Onatade R. *United Kingdom Clinical Pharmacy Association Symposium Proceedings*; 2016.
- ⁴Koo, T. K., & Li, M. Y. *Journal of chiropractic medicine* (2016); 15(2), 155-163

4CPS-241

